RN Mobile Menu

Search form


Rheumatoid Arthritis

Pneumococcal Vaccine Not for Senior RA Patients?

While PPSV23 is recommended for senior adults, researchers say there is "uncertainty" about its effectiveness in infection-prone senior adults with rheumatoid arthritis.


Rheumatoid Arthritis

Marcy B.Bolster, M.D.

Facing a growing shortage, rheumatology is looking to attract the next generation of providers.

Jonathan S. Hausmann, M.D.

Retaining international medical students, addressing student loan debt, mentoring and case-based teaching could possibly reverse the rheumatologist shortage, analysis says.

Baricitinib janus kinase inhibitor drug molecule. (Molekuul_be/Shutterstock.com)

Compared to placebo and adalimumab, the addition of once-daily oral baricitinib produced significant clinical improvements in RA patients, research shows.

Baricitinib janus kinase (JAK1 & JAK2) inhibitor drug molecule. (Molekuul_beShut

Patient-reported outcomes are in line with clinical trial results for baricitinib, an international research team reports.

(Combination medications  ©piotr_pabijan/Shutterstock.com)

Rheumatoid arthritis patients who fail previous methotrexate therapy respond better to TNFi–methotrexate combo, compared to a specific triple therapy, researchers say.

(Vaccinese ©adamgregor/Shutterstock.com)

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) does not prevent pneumonia in rheumatoid arthritis patients, a new study finds.

Elderly falls (©Toa55/Shutterstock.com)

Brain changes that occur as a result of small vessel disease negatively effect gait in senior patients, research shows.


Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.